141 related articles for article (PubMed ID: 10537316)
1. Apoptosis induction of human lung cancer cell line in multicellular heterospheroids with humanized antiganglioside GM2 monoclonal antibody.
Nakamura K; Hanibuchi M; Yano S; Tanaka Y; Fujino I; Inoue M; Takezawa T; Shitara K; Sone S; Hanai N
Cancer Res; 1999 Oct; 59(20):5323-30. PubMed ID: 10537316
[TBL] [Abstract][Full Text] [Related]
2. Chimeric anti-ganglioside GM2 antibody with antitumor activity.
Nakamura K; Koike M; Shitara K; Kuwana Y; Kiuragi K; Igarashi S; Hasegawa M; Hanai N
Cancer Res; 1994 Mar; 54(6):1511-6. PubMed ID: 8137257
[TBL] [Abstract][Full Text] [Related]
3. Chimeric and humanized anti-HM1.24 antibodies mediate antibody-dependent cellular cytotoxicity against lung cancer cells.
Wang W; Nishioka Y; Ozaki S; Jalili A; Verma VK; Hanibuchi M; Abe S; Minakuchi K; Matsumoto T; Sone S
Lung Cancer; 2009 Jan; 63(1):23-31. PubMed ID: 18524412
[TBL] [Abstract][Full Text] [Related]
4. Dissection and optimization of immune effector functions of humanized anti-ganglioside GM2 monoclonal antibody.
Nakamura K; Tanaka Y; Fujino I; Hirayama N; Shitara K; Hanai N
Mol Immunol; 2000 Dec; 37(17):1035-46. PubMed ID: 11399321
[TBL] [Abstract][Full Text] [Related]
5. Humanized anti-ganglioside GM2 antibody is effective to induce antibody-dependent cell-mediated cytotoxicity in mononuclear cells from lung cancer patients.
Parajuli P; Yanagawa H; Hanibuchi M; Takeuchi E; Miki T; Yano S; Sone S
Cancer Lett; 2001 Apr; 165(2):179-84. PubMed ID: 11275367
[TBL] [Abstract][Full Text] [Related]
6. Recombinant antibodies against ganglioside expressed on tumor cells.
Hanai N; Nakamura K; Shitara K
Cancer Chemother Pharmacol; 2000; 46 Suppl():S13-7. PubMed ID: 10950141
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a proapoptotic antiganglioside GM2 monoclonal antibody and evaluation of its therapeutic effect on melanoma and small cell lung carcinoma xenografts.
Retter MW; Johnson JC; Peckham DW; Bannink JE; Bangur CS; Dresser K; Cai F; Foy TM; Fanger NA; Fanger GR; Woda B; Rock KL
Cancer Res; 2005 Jul; 65(14):6425-34. PubMed ID: 16024647
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic efficacy of mouse-human chimeric anti-ganglioside GM2 monoclonal antibody against multiple organ micrometastases of human lung cancer in NK cell-depleted SCID mice.
Hanibuchi M; Yano S; Nishioka Y; Yanagawa H; Kawano T; Sone S
Int J Cancer; 1998 Nov; 78(4):480-5. PubMed ID: 9797137
[TBL] [Abstract][Full Text] [Related]
9. Anti-ganglioside GM2 monoclonal antibody-dependent killing of human lung cancer cells by lymphocytes and monocytes.
Hanibuchi M; Yano S; Nishioka Y; Yanagawa H; Sone S
Jpn J Cancer Res; 1996 May; 87(5):497-504. PubMed ID: 8641987
[TBL] [Abstract][Full Text] [Related]
10. Binding activities and antitumor properties of a new mouse/human chimeric antibody specific for GD2 ganglioside antigen.
Alvarez-Rueda N; Leprieur S; Clémenceau B; Supiot S; Sébille-Rivain V; Faivre-Chauvet A; Davodeau F; Paris F; Barbet J; Aubry J; Birklé S
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5613s-5620s. PubMed ID: 17875797
[TBL] [Abstract][Full Text] [Related]
11. Genetically engineered humanized anti-ganglioside GM2 antibody against multiple organ metastasis produced by GM2-expressing small-cell lung cancer cells.
Yamada T; Bando H; Takeuchi S; Kita K; Li Q; Wang W; Akinaga S; Nishioka Y; Sone S; Yano S
Cancer Sci; 2011 Dec; 102(12):2157-63. PubMed ID: 21895875
[TBL] [Abstract][Full Text] [Related]
12. The role of cyclosporin A on antibody-dependent monocyte-mediated cytotoxicity against human multidrug-resistant cancer cells.
Yano S; Yanagawa H; Hanibuchi M; Pai K; Nishioka Y; Tsuruo T; Sone S
J Med Invest; 1998 Feb; 44(3-4):185-91. PubMed ID: 9597807
[TBL] [Abstract][Full Text] [Related]
13. Complement-mediated anti-HIV-1 effect induced by human IgM monoclonal antibody against ganglioside GM2.
Wu X; Okada N; Momota H; Irie RF; Okada H
J Immunol; 1999 Jan; 162(1):533-9. PubMed ID: 9886430
[TBL] [Abstract][Full Text] [Related]
14. Humanized anti-Lewis Y antibodies: in vitro properties and pharmacokinetics in rhesus monkeys.
Co MS; Baker J; Bednarik K; Janzek E; Neruda W; Mayer P; Plot R; Stumper B; Vasquez M; Queen C; Loibner H
Cancer Res; 1996 Mar; 56(5):1118-25. PubMed ID: 8640770
[TBL] [Abstract][Full Text] [Related]
15. Effect of a chimeric anti-ganglioside GM2 antibody on ganglioside GM2-expressing human solid tumors in vivo.
Fukumoto H; Nishio K; Ohta S; Hanai N; Fukuoka K; Ohe Y; Sugihara K; Kodama T; Saijo N
Int J Cancer; 1999 Aug; 82(5):759-64. PubMed ID: 10417777
[TBL] [Abstract][Full Text] [Related]
16. Reactivity of a mouse/human chimeric anti-GM2 antibody KM966 with brain tumors.
Dohi T; Nakamura K; Hanai N; Taomoto K; Oshima M
Anticancer Res; 1994; 14(6B):2577-81. PubMed ID: 7872684
[TBL] [Abstract][Full Text] [Related]
17. Humanized anti-CD26 monoclonal antibody as a treatment for malignant mesothelioma tumors.
Inamoto T; Yamada T; Ohnuma K; Kina S; Takahashi N; Yamochi T; Inamoto S; Katsuoka Y; Hosono O; Tanaka H; Dang NH; Morimoto C
Clin Cancer Res; 2007 Jul; 13(14):4191-200. PubMed ID: 17634548
[TBL] [Abstract][Full Text] [Related]
18. Lysis of human tumor cell lines by canine complement plus monoclonal antiganglioside antibodies or natural canine xenoantibodies.
Helfand SC; Hank JA; Gan J; Sondel PM
Cell Immunol; 1996 Jan; 167(1):99-107. PubMed ID: 8548851
[TBL] [Abstract][Full Text] [Related]
19. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
[TBL] [Abstract][Full Text] [Related]
20. Reactivities of mouse monoclonal antibody K2.7 to renal cancers in complement dependent cytotoxicity and antibody dependent cell-mediated cytotoxicity.
Kinouchi T; Bander NH; Kotake T
J Urol; 1995 Jul; 154(1):288-92. PubMed ID: 7776448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
